WHO Approves Ensifentrine as Name for Potential Inhaled Treatment Now in Clinical Trials
cystic fibrosis, News
The World Health Organization (WHO) approved ensifentrine as the recommended name to identify the cystic fibrosis (CF) treatment candidate RPL554. Verona Pharma’s ensifentrine is an inhaled inhibitor of the enzymes phosphodiesterase ... Read more